Business
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France, May 28, 2026--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
About this update from Medincell Sa
MONTPELLIER, France, May 28, 2026 --( BUSINESS WIRE )--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. Videoconference in English, 6:00pm CEST / 12:00pm ET > https://www.medincell.com/annual-results-2025-2026-register/ During the videoconference, Medincell’s management team will provide an overview of the company’s performance and strategic outlook, followed by a Q&A session in English. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. These treatments combine active pharmaceutical ingredients with our proprietary BEPO ® / BEPO ® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot. Medincell’s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options. Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities. medincell.com UZEDY ® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO ® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals. View source version on businesswire.com: https://www.businesswire.com/news/home/20260528020839/en/ Contacts David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] / +33 (0)6 83 25 21 86 Grace Kim Chief Strategy Officer, U.S. Finance [email protected] / +1 (646) 991-4023 Nicolas Mérigeau Media Relations [email protected] / +33 (0)1 44 71 94 94 Louis-Victor Delouvrier / Alban Dufumier Investor Relations France [email protected] / +33 (0)1 44 71 94 94